'Big Hands' Shopping for Korean Firms: Global Capital Sets Its Sights …
페이지 정보
작성자 playbbs 작성일 26-06-10 04:56 조회 344 댓글 0본문
'Big Hands' Shopping for Korean Companies: Global Capital Sets Its Sights on KT&G and the Biotech Sector
Date: June 10, 2026 | Column by IT/Media Current Affairs Critic
Recently, the stock market has been buzzing as massive global asset management firms have been aggressively courting blue-chip Korean companies. So-called "global big hands," such as BlackRock and Capital Group—which manage assets worth thousands of trillions of won—are successively acquiring stakes in specific companies, drawing significant attention to the motives behind these moves. Going beyond mere shareholding, their actions, driven by a long-term perspective and confidence in the structural improvement and growth potential of Korean firms, are sending positive signals across the market. It is time to closely examine the core competitiveness of the Korean companies they are eyeing and the impact this large-scale capital inflow will have on the domestic stock market.
KT&G has emerged as one of the hottest stocks among global asset managers. Following BlackRock, Capital Group has also raised its stake to the 7% range, signaling strong confidence. This is not a coincidental investment but a result of conviction in the company's fundamentals. KT&G has achieved record growth in its overseas cigarette business through strategic pricing power and efficient cost management. In fact, the company recorded a "triple crown" in the first quarter, with growth in revenue, operating profit, and sales volume, further solidifying its position in the global market. Such performance-based growth serves as a highly attractive indicator for conservative global investors.
Another key driver behind KT&G capturing the hearts of global capital is its strong commitment to shareholder returns. The company has already carried out large-scale treasury stock cancellations to enhance shareholder value and has signaled a new shareholder return policy for the second half of the year, centered on increased dividends. Management, led by CEO Bang Kyung-man, has emphasized shareholder-centric capital allocation principles and pledged to establish a virtuous cycle where business performance is shared with shareholders. Such transparent and forward-looking shareholder-friendly policies are evaluated as highly positive investment factors by global institutional investors focused on long-term growth.
The movement of global big hands is also notable in the biotech sector. In the case of HLB, BlackRock, the world's largest asset manager, has increased its stake to the 6% range, heightening market expectations. Market analysts interpret this move by BlackRock as targeting the momentum of new drug approvals scheduled for the second half of the year. In particular, with HLB awaiting US FDA approval decisions for key pipelines such as its first-line liver cancer treatment and bile duct cancer treatment, there is a high possibility of a significant surge in corporate value if the results are successful. This is a case that proves the technological prowess of domestic biotech companies is being recognized in the global market, rather than being a mere investment.
Yuhan Corporation is also gaining attention as a new addition to BlackRock's investment portfolio. BlackRock has secured over a 5% stake in Yuhan, becoming a major institutional investor. This appears to be the result of a high valuation of the global commercialization success of its lung cancer drug 'Leclaza' and the potential for additional technology exports. With a solid financial structure already in place, the competitiveness of Yuhan's new drug pipeline is strengthening its mid-to-long-term growth momentum. As global capital joins the National Pension Service in betting on Yuhan's future value, the company's status within the pharmaceutical and biotech market is expected to rise further.
The common investment strategy of these global asset managers can be summarized as "long-term investment in blue-chip stocks with proven growth potential." Institutions like BlackRock and Capital Group focus on a company's intrinsic competitiveness and sustainable business models rather than short-term price gains. Therefore, their increased stakes serve as a report card proving that these companies possess transparent management and solid profit-generating capabilities that meet global standards. Furthermore, as their approach is based on portfolio diversification and value investing rather than participating in management rights, they present an ideal model that maintains corporate independence while earning the trust of global investors.
■ Conclusion and Outlook
The investment of global big hands in Korean companies is injecting new vitality into our market. The stable earnings growth and shareholder return policies of KT&G, along with the new drug approval momentum of biotech companies represented by HLB and Yuhan, show that global capital's perspective on the Korean market has become more sophisticated. This large-scale capital inflow will serve as a positive catalyst, going beyond mere stock price boosting, to encourage domestic companies to achieve global-level transparency and competitiveness. We look forward to a virtuous cycle where Korean companies continue to earn the lasting trust of global investors through tangible results, thereby resolving the "Korea Discount" and seeing their corporate value re-evaluated.
* This post is an analytical column automatically regenerated in the style of a current affairs critic by analyzing real-time Google Trends popular search terms and related major articles.
댓글목록 0
등록된 댓글이 없습니다.